48 related articles for article (PubMed ID: 37690663)
1. Predictive and prognostic biomarkers in urological tumours.
Cimadamore A; Franzese C; Di Loreto C; Blanca A; Lopez-Beltran A; Crestani A; Giannarini G; Tan PH; Carneiro BA; El-Deiry WS; Montironi R; Cheng L
Pathology; 2024 Mar; 56(2):228-238. PubMed ID: 38199927
[TBL] [Abstract][Full Text] [Related]
2. Management of Renal Cell Carcinoma: Promising Biomarkers and the Challenges to Reach the Clinic.
Lyskjær I; Iisager L; Axelsen CT; Nielsen TK; Dyrskjøt L; Fristrup N
Clin Cancer Res; 2024 Feb; 30(4):663-672. PubMed ID: 37874628
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Prostate and Bladder Cancer Genomic Biomarkers Using Artificial Intelligence: a Systematic Review.
Bazarkin A; Morozov A; Androsov A; Fajkovic H; Rivas JG; Singla N; Koroleva S; Teoh JY; Zvyagin AV; Shariat SF; Somani B; Enikeev D
Curr Urol Rep; 2024 Jan; 25(1):19-35. PubMed ID: 38099997
[TBL] [Abstract][Full Text] [Related]
4. Clinical translational research of liquid biopsy applications in prostate cancer and other urological cancers.
Huang J; Huang D; Ruan X; Zhan Y; Chun ST; Ng AT; Na R
Camb Prism Precis Med; 2023; 1():e33. PubMed ID: 38550929
[TBL] [Abstract][Full Text] [Related]
5. Metabolomics Biomarkers of Prostate Cancer: A Systematic Review.
Kdadra M; Höckner S; Leung H; Kremer W; Schiffer E
Diagnostics (Basel); 2019 Feb; 9(1):. PubMed ID: 30791464
[TBL] [Abstract][Full Text] [Related]
6. Pharmacometabolomics Applied to Personalized Medicine in Urological Cancers.
Amaro F; Carvalho M; Bastos ML; Guedes de Pinho P; Pinto J
Pharmaceuticals (Basel); 2022 Feb; 15(3):. PubMed ID: 35337093
[TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
8. Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies.
Ellinger J; Müller DC; Müller SC; Hauser S; Heukamp LC; von Ruecker A; Bastian PJ; Walgenbach-Brunagel G
Urol Oncol; 2012; 30(4):509-15. PubMed ID: 20870429
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
Geybels MS; Wright JL; Bibikova M; Klotzle B; Fan JB; Zhao S; Feng Z; Ostrander EA; Lin DW; Nelson PS; Stanford JL
Clin Epigenetics; 2016; 8():97. PubMed ID: 27651837
[TBL] [Abstract][Full Text] [Related]
11. Metabolic signature biomarkers for predicting the recurrence of urological cancers.
Amaro F; Carvalho M; Bastos ML; Guedes de Pinho P; Pinto J
Clin Chim Acta; 2023 Sep; 549():117553. PubMed ID: 37690663
[TBL] [Abstract][Full Text] [Related]
12. Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data.
Speed JM; Trinh QD; Choueiri TK; Sun M
Curr Urol Rep; 2017 Feb; 18(2):15. PubMed ID: 28213859
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]